Objective: To determine human immunodeficiency virus (HIV) type 1 genotypic antiretroviral drug resistance profiles of patients presenting a risk or potential risk for occupational exposure of healthcare workers.

Design: Observational survey involving HIV-infected patients. Blood samples collected from source-patients and potential source-patients underwent HIV-1 genotypic antiretroviral resistance testing and determination of CD4 counts and viral load. Affected healthcare workers were monitored for 6 months after exposure.

Setting: The survey was conducted in a tertiary-care hospital located in Sao Paulo, Brazil. Sao Paulo is considered the epicenter of the HIV-acquired immunodeficiency (AIDS) virus epidemic in Brazil.

Participants: Source-patients, potential source-patients, and affected healthcare workers.

Results: A total of 371 occupational exposures to biological materials were reported, 46 (12.3%) of which were from HIV-seropositive source-patients. Samples from 18 source-patients and 26 patients considered "potential sources for accidents" were analyzed. Of these 44 samples, 18 (41%) presented resistance-related mutations in reverse transcriptase, protease, or both. Of these 18 samples, 16 (89%) had resistance to drugs included in the prophylactic schedule recommended by the Brazilian Ministry of Health.

Conclusions: Use of the Centers for Disease Control and Prevention-Brazilian post-exposure prophylaxis regimen will result in the administration of antiretroviral agents to which the source HIV-1 isolate will often be resistant. Therefore, it would be advisable to carefully investigate the history of use of antiretroviral agents by source-patients and adjust the prophylactic therapy based on those data and, subsequently, the results of resistance testing.

Download full-text PDF

Source
http://dx.doi.org/10.1086/502617DOI Listing

Publication Analysis

Top Keywords

antiretroviral drug
8
drug resistance
8
human immunodeficiency
8
immunodeficiency virus
8
healthcare workers
8
genotypic antiretroviral
8
source-patients potential
8
potential source-patients
8
resistance testing
8
sao paulo
8

Similar Publications

Age-specific abnormal glucose metabolism in HIV-positive people on antiviral therapy in China: a multicenter case-control study.

Ann Med

December 2025

Department of Emergency Medicine, Second Affiliated Hospital, Department of Public Health, The Key Laboratory of Intelligent Preventive Medicine of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China.

Background: Update, the link between HIV infection and abnormal glucose metabolism (AGM) is still unclear. This study aims to investigate the impact of HIV infection on AGM, including insulin resistance (IR), impaired fasting glucose (IFG), and diabetes mellitus (DM).

Methods: A multicenter case-control study was conducted in Zhejiang province, China.

View Article and Find Full Text PDF

[Incidence and risk factors of anemia among newly reported HIV/AIDS patients in Jiangsu Province in 2021].

Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi

December 2024

School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 210000, China.

Objective: To investigate the incidence of anemia and evaluate the immune status among newly reported HIV/AIDS patients in Jiangsu Province in 2021, and to identify the risk factors of anemia among patients living with HIV infections.

Methods: Newly reported HIV/AIDS patients in Jiangsu Province from January 1 to December 31, 2021 that were registered in China's National AIDS Comprehensive Control Information Management System were enrolled. Subjects' fresh whole blood samples were collected, and hemoglobin levels, CD4 and CD8 cell counts and HIV viral loads were measured.

View Article and Find Full Text PDF

Background: Hepatitis C virus (HCV) infections and injection drug use have concurrently increased in the last decade. Evidence supports simultaneously treating chronic HCV and opioid use disorder (OUD) with medication. Kentucky is a hard-hit state for both conditions that has undertaken policy and practice efforts to increase access to both types of medications.

View Article and Find Full Text PDF

The only current strategy to test efficacy of novel interventions for sustained HIV control without antiretroviral therapy (ART) among people with HIV (PWH) is through an analytical treatment interruption (ATI). Inclusion of 'placebo' controls in ATIs poses ethical, logistical, and economic challenges. To understand viral dynamics and rates of post-treatment control (PTC) after ATI among PWH receiving either placebo or no intervention, we undertook an individual-participant data meta-analysis.

View Article and Find Full Text PDF

Drug interactions in HIV patients treated with antivirals for other viral illnesses.

Expert Opin Drug Metab Toxicol

January 2025

Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, New Haven, CT.

Introduction: Background:People with HIV (PWH) have benefited tremendously from effective antiretroviral (ARV) treatments. However, PWH are at increased risk for other viral infections transmitted in the same way as HIV (such as hepatitis C and MPox) or that are opportunistic (e.g.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!